Over the past several years, GLP-1 receptor agonists have fundamentally reshaped conversations surrounding obesity management, metabolic disease, and long-term health. Medications such as semaglutide and tirzepatide have introduced levels of weight-loss efficacy that, until recently, were difficult to achieve outside of bariatric surgery. However, retatrutide appears to represent something categorically different. Rather than simply improving upon earlier GLP-1 medications, this emerging triple agonist may signal the beginning of an entirely new era in obesity pharmacotherapy.

Retatrutide simultaneously targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, combining appetite suppression, enhanced glycemic regulation, and increased energy expenditure into a single therapeutic approach (Madsbad & Holst, 2025; Sanyal et al., 2024). Early preclinical investigations involving next-generation GLP-1/GIP/glucagon tri-agonists demonstrated profound normalization of body weight and metabolic regulation in obese animal models long before retatrutide entered broader clinical discussion (Knerr et al., 2022). In many ways, current human trials appear to represent the translational continuation of those earlier mechanistic findings.

Early clinical findings now suggest that this tri-agonist model may produce weight loss that approaches or even rivals bariatric surgery outcomes, with some studies reporting reductions of up to 24% of total body weight over approximately 48 weeks (Locatelli et al., 2024; Madsbad & Holst, 2025).

For personal trainers, this is not simply another “weight loss drug” discussion. It represents a rapidly evolving physiological, behavioral, and professional landscape that may fundamentally alter what clients need from coaches moving forward.

Why Retatrutide Represents a Different Conversation

Much of the public conversation surrounding obesity pharmacotherapy has understandably focused on appetite suppression. While this is certainly part of the equation, retatrutide’s mechanisms appear considerably more complex.

GLP-1 receptor activation primarily reduces caloric intake through central appetite regulation and delayed gastric emptying, with transcriptomic analyses suggesting highly specialized hypothalamic receptor signaling involved in the regulation of appetite and feeding behavior (Smith et al., 2022). GIP receptor activation may additionally increase energy expenditure through adipocyte thermogenesis and metabolic signaling pathways involving SERCA-mediated calcium cycling (Yu et al., 2024). Meanwhile, glucagon receptor activation appears to further enhance lipolysis, thermogenesis, and metabolic flexibility through mechanisms influencing systemic energy homeostasis and substrate utilization (González-García et al., 2019).

Collectively, these mechanisms create what may be the most metabolically aggressive obesity pharmacotherapy currently under investigation.

That distinction matters because the conversation is no longer simply:

• “How do we help clients lose weight?”

Instead, the question increasingly becomes:

• “How do we help clients adapt to rapid physiological change without compromising long-term muscle quality, function, recovery, and performance?”

That is an entirely different coaching challenge.

The Emerging Muscle Preservation Problem

Despite retatrutide’s remarkable efficacy, one issue repeatedly emerges throughout the literature: substantial lean mass loss frequently accompanies rapid weight reduction.

Current evidence suggests that more than 25% of the total weight lost during incretin-based pharmacotherapy may be attributable to fat-free mass, including skeletal muscle tissue (Locatelli et al., 2024). In some studies, lean mass reductions approached approximately 10% of total body weight, or nearly 6 kilograms over 48–72 weeks (Mechanick et al., 2024).

To place this into perspective, researchers have noted that this degree of lean tissue loss may approximate a decade or more of age-related sarcopenic decline (Vikberg et al., 2019). This becomes particularly concerning in aging populations already vulnerable to reductions in muscle strength, physical function, and long-term independence.

This creates a significant paradox.

An individual may lose substantial body weight, improve glycemic markers, and appear healthier externally while simultaneously becoming weaker, less metabolically resilient, and potentially more vulnerable to functional decline.

In many ways, retatrutide may force the fitness industry to confront an uncomfortable but increasingly important question: Is smaller always healthier?

From a muscle-centric perspective, the answer is considerably more nuanced.

“Protein Intake, Recovery, and Resistance Training Become Foundational” Section

As I alluded to in my earlier series on personal training in the era of GLP-1 agonists, another major implication of profound appetite suppression is an increased risk of under-consuming protein and other essential nutrients.

The literature consistently recommends elevated protein intakes during incretin therapy, generally ranging from approximately 1.6–2.2 g/kg/day, considerably higher than standard dietary recommendations for sedentary populations (Phillips, 2014).

This becomes especially important because caloric restriction shifts muscle protein turnover toward net proteolysis, increasing the risk of muscle degradation if resistance training and protein intake are insufficient (Mechanick et al., 2024; Phillips, 2014).

In practical terms, many clients using potent incretin therapies may eat dramatically less, unintentionally under-consume protein, recover poorly, and lose muscle despite “successful” weight loss.

As a result, trainers may increasingly need to understand protein distribution, leucine-rich nutrition strategies, recovery management, and resistance training progression during caloric restriction. This becomes especially relevant given emerging evidence supporting leucine-enriched whey protein interventions as potentially valuable strategies for attenuating sarcopenia-related muscle loss during periods of physiological stress and reduced intake (Cereda et al., 2022).

These are no longer niche coaching topics. They are rapidly becoming foundational competencies.

The Future of Muscle-Centric Coaching

Perhaps the most important implication of the retatrutide era is that it forces the fitness industry to reconsider what transformation actually means.

For decades, scale weight reduction served as the dominant marker of success. However, as pharmacotherapy becomes increasingly capable of producing dramatic body weight changes, the true differentiator may become:

• muscle preservation,
• physical function,
• metabolic resilience,
• and long-term sustainability.

In this regard, personal trainers may increasingly function less as “fat-loss coaches” and more as:

• muscle-preservation specialists,
• recovery strategists,
• and performance-oriented behavior-change professionals.

That evolution is significant. While medications may continue improving at inducing weight loss, they cannot:

• teach movement competency,
• progressively overload a squat,
• improve power output,
• optimize recovery habits,
• or help clients sustain identity-level behavior change over time.

Those remain profoundly human coaching tasks.

Conclusion

Retatrutide represents far more than another obesity medication. It may represent the beginning of a fundamentally new era in metabolic medicine.

Its unprecedented efficacy introduces enormous potential benefits for obesity management, glycemic control, cardiovascular risk reduction, and quality of life. At the same time, the rapid physiological changes associated with these therapies introduce important questions surrounding skeletal muscle preservation, recovery capacity, functional performance, and sustainable long-term adaptation.

For personal trainers, this changing landscape creates both challenge and opportunity.

The professionals who thrive in the future may not simply be those who help clients lose weight. They may be the coaches who help clients preserve strength, maintain muscle, improve function, and navigate rapid physiological change intelligently and sustainably.

In many ways, the retatrutide era may elevate the importance of muscle-centric coaching more than ever before.

References 

Cereda, E., Pisati, R., Rondanelli, M., & Caccialanza, R. (2022). Whey protein, leucine- and vitamin D-enriched oral nutritional supplementation for the treatment of sarcopenia. Nutrients, 14(7), 1524. https://doi.org/10.3390/nu14071524

González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019). Glucagon receptor signaling and energy homeostasis. Molecular and Cellular Endocrinology, 418, 28–37.

Knerr, P. J., et al. (2022). Next-generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular Metabolism, 63, 101533. https://doi.org/10.1016/j.molmet.2022.101533

Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L., Fegan, P., Yeap, B. B., & Green, D. J. (2024). Incretin-based weight loss pharmacotherapy: Can resistance exercise optimize changes in body composition? Diabetes Care, 47(10), 1734–1742. https://doi.org/10.2337/dci23-0100  

Madsbad, S., & Holst, J. J. (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: A look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs, 34(3), 197–215. https://doi.org/10.1080/13543784.2025.2472408 

Phillips, S. M. (2014). A brief review of critical processes in exercise-induced muscular hypertrophy. Sports Medicine, 44(Suppl. 1), S71–S77.

Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M., Harris, C., Schloot, N. C., Du, Y., Mather, K., Haupt, A., & Hartman, M. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nature Medicine, 30(8), 2214–2223. https://doi.org/10.1038/s41591-024-03018-2

Smith, C. A., Patterson-Cross, R. B., Woodward, O. R. M., Lewis, J., Chiarugi, D., Merkle, F., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2022). A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus. Appetite, 177, 106022. https://doi.org/10.1016/j.appet.2022.106022

Vikberg, S., Sörlén, N., Brännström, M., Bucht, G., Stenlund, H., & Rosendahl, E. (2019). Effects of resistance training on functional strength and muscle mass in older adults with sarcopenia. Journal of the American Medical Directors Association, 20(1), 28–34.

Yu, Y., et al. (2024). GIP receptor agonism enhances adipocyte thermogenesis and metabolic regulation. Cell Metabolism, 36(2), 214–228.